ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US
August 26, 2020MC2 Therapeutics retains full ownership of WYNZORA Cream under the Collaboration Agreement and MC2 Therapeutics and EPI Health will utilize their combined resources to make WYNZORA Cream a leading patient preferred topical treatment of psoriasis in the US -
MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for Adults with Plaque Psoriasis
July 28, 2020MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved Wynzora® Cream (calcipotriene and
Pharma Sources Insight January 2025
